

Funding sources

Lung Cancer Europe

2019

LuCE industry related income		
Name of company/funder	Amount of income	% of overall organisations income
AMGEN	28.749,75 CHF	8,76%
ARES TRADING	11.450,20 CHF	3,49%
ASTRAZENECA	22.832,40 CHF	6,96%
BLUEPRINT	9.755,75 CHF	2,97%
BOEHRINGER INGELHEIM	28.590,00 CHF	8,71%
BRISTOL-MYERS	30.052,35 CHF	9,16%
CELGENE	13.683,95 CHF	4,17%
ELI LILLY	22.551,40 CHF	6,87%
HOFFMANN-LA ROCHE	35.000,00 CHF	10,67%
MSD INTERNATIONAL	34.308,00 CHF	10,46%
NOVARTIS	17.283,60 CHF	5,27%
PFIZER	28.214,25 CHF	8,60%
TAKEDA	25.218,60 CHF	7,69%
OTHER REFUNDS INDUSTRY	18.347,70 CHF	5,59%
Subtotal	326.037,95 CHF	99,37%

LuCE non-industry related income – Public funding		
Name of company/funder	Amount of income	% of overall organisations income
None	-	0,00%
Subtotal	-	0,00%

LuCE non-industry related income		
Name of company/funder	Amount of income	% of overall organisations income
Members contribution	1.511,25 CHF	0,46%
ESO – European School of Oncology	554,50 CHF	0,17%
Other refunds non-industry	-	0,00%
Subtotal	2.065,75 CHF	0,63%

TOTAL	328.103,70 CHF	100,00%
--------------	-----------------------	----------------

Summary

Overall proportion of industry and non-industry

Industry: 99.37%; Non-Industry: 0.63%

Percentage of the highest contribution from a single company

10.67 % of overall organizations income